CYP19A1 and benign prostatic hyperplasia: Based on in vitro studies, numerous biological activities such as 5a-reductase inhibition, androgen blockade aromatase activity, inhibition of prostaglandin synthesis, a1-blockade and anti-inflammatory activity have been postulated as mechanisms of action in BPH [10].